China Pharmaceutical University and the Chongqing Innovation Institute, China Pharmaceutical University have synthesized new asiaticoside saponin compounds reported to be useful for the treatment of inflammation, cancer and ulcerative colitis.
Army Medical University has identified new cyclic GMP-AMP synthase (MB21D1; cGAS)/STING pathway inhibitors potentially useful for the treatment of inflammatory disorders.
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that autoimmunity might underlie the persistent neurological symptoms seen in long COVID, researchers at Yale University and Mount Sinai now reinforce this hypothesis. SARS-CoV-2 infection appears to trigger an autoimmune mechanism that drives chronic pain, fatigue and cognitive impairment in some patients.
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.
Beijing Tide Pharmaceutical Co. Ltd. has divulged new salts of known angiotensin AT2 recpetor antagonists potentially useful for the treatment of allergy, autoimmune and demyelinating diseases, cerebrovascular, respiratory, cognitive, gastrointestinal and inflammatory disorders, among others.
Neurolambda Therapeutics Inc. has disclosed new non-receptor tyrosine-protein kinase TYK2 inhibitors potentially useful for the treatment of cancer, systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis.
Researchers from the University of Copenhagen and collaborating institutions aimed to develop a therapy for chronic neuropathic pain based on gene therapy delivered with adeno-associated viral (AAV) vectors.
Korean researchers reported the discovery and preclinical characterization of KSI-028, a novel tetrahydroquinoline-based STING inhibitor with activity across multiple models of STING activation.
Aeovian Pharmaceuticals Inc. has divulged new ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of neurodegeneration, inflammation, fibrosis, systemic scleroderma, vascular disorders, Duchenne muscular dystrophy, liver and metabolic diseases, among others.
Boehringer Ingelheim Pharma GmbH & Co. KG and Immunitas Therapeutics Inc. have signed a global licensing agreement for a preclinical antibody program being developed for chronic inflammatory and autoimmune diseases.
RSS
